We are entering a new and exciting era of medicine. New technological advances in artificial intelligence (AI), multiomics and regenerative medicine bring unprecedented promise to the realization of personalized medicine. The future of medicine and the future of healthcare are dependent on the translation of these innovations into new diagnostics and therapeutics which could profoundly impact patient care delivery. We are therefore delighted and proud to launch MedComm – Future Medicine, a new Wiley journal. MedComm – Future Medicine is an open-access journal which will publish the latest and most impactful biomedical research. We are a multidisciplinary journal with special interest in multiomics, bioinformatics, medical AI, stem cell and regenerative medicine, and gene therapy. Our articles in medicine and biology will be reviewed and assessed on the basis of novelty, timeliness and significance to human health and diseases. We will cover the latest advances in biomedical research that improve our understanding of diseases, address unmet medical needs, and have the potential to transform healthcare. We have assembled a world-class editorial board, led by our Editors-In-Chief Professor Robin Ali, Professor Michael Karin, and Professor Kang Zhang. The editorial board members consist of an international group of leading experts in their research domains. Our mission at the editorial board is to ensure your best research is subjected to the highest quality and rigorous peer-review in a timely fashion. We also have dedicated editorial staff who co-ordinate the peer review process, production of your accepted articles and marketing of MedComm – Future Medicine. We will ensure that your paradigm-shifting discoveries will receive the highest quality production, and reach the widest readership. MedComm – Future Medicine is born at a time of global healthcare emergency. The Covid-19 pandemic has put into focus the importance of international collaborative efforts, which have resulted in an unprecedented increase in research output. Effective review and dissemination of this information is indispensable to maximizing research impact and public engagement. MedComm – Future Medicine aspires to be at the nexus of translational research advances. The success of MedComm – Future Medicine will be a testament to the global community of scientists and researchers who contribute to the journal's contents, review process and citations. We hope you will enjoy reading our contents and consider submitting your next paradigm-shifting research findings to MedComm – Future Medicine. Together, we hope to transform the future of medicine!
Discussion(0)
No comments yet. Be the first to comment.